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Abstract: Purpose To evaluate the value of a browser-based PI-RADS Score Calculator (PCalc) compared
to MRI reporting using the official PI-RADS v2.1 document (PDoc) for non-specialized radiologists in
terms of reporting efficiency, interrater agreement and diagnostic accuracy for detection of clinically
significant prostate cancer (PCa). Methods Between 09/2013 and 04/2015, 100 patients (median age,
64.8; range 47.5-78.2) who underwent prostate-MRI at a 3 T scanner and who received transperineal
prostate mapping biopsy within <6 months were included in this retrospective study. Two non-specialized
radiology residents (R1, R2) attributed a PI-RADS version 2.1 score for the most suspect (i. e. index)
lesion (i) using the original PI-RADS v2.1 document only and after a 6-week interval (ii) using a browser-
based PCalc. Reading time was measured. Reading time differences were assessed using Wilcoxon
signed rank test. Intraclass-correlation Coefficient (ICC) was used to assess interrater agreement (IRA).
Parameters of diagnostic accuracy and ROC curves were used for assessment of lesion-based diagnostic
accuracy. Results Cumulative reading time was 32:55 (mm:ss) faster when using the PCalc, the difference
being statistically significant for both readers (p < 0.05). The difference in IRA between the image sets
(ICC 0.55 [0.40, 0.68]) and 0.75 [0.65, 0.82] for the image set with PDoc and PCalc, respectively) was not
statistically significant. There was no statistically significant difference in lesion-based diagnostic accuracy
(AUC 0.83 [0.74, 0.92] and 0.82 [95 %CI: 0.74, 0.91]) for images assessed with PDoc as compared to
PCalc (AUC 0.82 [0.74, 0.91] and 0.74 [95 %CI: 0.64, 0.83]) for R1 and R2, respectively. Conclusion Non-
specialized radiologists may increase reading speed in prostate MRI with the help of a browser-based
PI-RADS Score Calculator compared to reporting using the official PI-RADS v2.1 document without
impairing interreader agreement or lesion-based diagnostic accuracy for detection of clinically significant
PCa.
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H I G H L I G H T S  
• A PI-RADS Score Calculator may significantly fasten the reporting process in Prostate MRI. 
• Increased PI-RADS v2.1 reporting speed does not translate into lower diagnostic accuracy. 
• Particularly non-expert radiologists may profit in terms of prostate MRI reporting efficiency.  






A B S T R A C T   
Purpose: To evaluate the value of a browser-based PI-RADS Score Calculator (PCalc) compared to MRI reporting 
using the official PI-RADS v2.1 document (PDoc) for non-specialized radiologists in terms of reporting efficiency, 
interrater agreement and diagnostic accuracy for detection of clinically significant prostate cancer (PCa). 
Methods: Between 09/2013 and 04/2015, 100 patients (median age, 64.8; range 47.5−78.2) who underwent 
prostate-MRI at a 3 T scanner and who received transperineal prostate mapping biopsy within <6 months were 
included in this retrospective study. Two non-specialized radiology residents (R1, R2) attributed a PI-RADS 
version 2.1 score for the most suspect (i. e. index) lesion (i) using the original PI-RADS v2.1 document only 
and after a 6-week interval (ii) using a browser-based PCalc. Reading time was measured. Reading time dif-
ferences were assessed using Wilcoxon signed rank test. Intraclass-correlation Coefficient (ICC) was used to assess 
interrater agreement (IRA). Parameters of diagnostic accuracy and ROC curves were used for assessment of 
lesion-based diagnostic accuracy. 
Results: Cumulative reading time was 32:55 (mm:ss) faster when using the PCalc, the difference being statistically 
significant for both readers (p < 0.05). The difference in IRA between the image sets (ICC 0.55 [0.40, 0.68]) and 
0.75 [0.65, 0.82] for the image set with PDoc and PCalc, respectively) was not statistically significant. There was 
no statistically significant difference in lesion-based diagnostic accuracy (AUC 0.83 [0.74, 0.92] and 0.82 [95 % 
CI: 0.74, 0.91]) for images assessed with PDoc as compared to PCalc (AUC 0.82 [0.74, 0.91] and 0.74 [95 %CI: 
0.64, 0.83]) for R1 and R2, respectively. 
Conclusion: Non-specialized radiologists may increase reading speed in prostate MRI with the help of a browser- 
based PI-RADS Score Calculator compared to reporting using the official PI-RADS v2.1 document without 
impairing interreader agreement or lesion-based diagnostic accuracy for detection of clinically significant PCa.   
1. Introduction 
The Prostate Imaging and Reporting Data System (PI-RADS), 
developed in a joint collaboration by the European Society of Urogenital 
Radiology (ESUR) and the American College of Radiology (ACR), serves 
the purpose to standardize acquisition and interpretation of 
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multiparametric prostate MRI. It has been evaluated and compared to 
non-standardized reporting [1–4] and has been revised twice, with 
version 2.1 [5] being the most current revision of the document. Today, 
PI-RADS is widely accepted in the radiologic and urologic community 
for reporting MRI of the prostate. 
Strictly cohering to the PI-RADS rules while interpreting a prostate 
MRI can be challenging. First, several features which differ based on 
lesion location, morphology and contrast uptake kinetics have to be 
assessed on multiple sequences for each lesion and a diagnostic algo-
rithm has to be followed to attain a final PI-RADS score. This process can 
be time-consuming. As cost of care and efficacy have increasingly 
become important factors in healthcare in general, reporting time has 
become an important performance indicator. Second, lesion 
morphology very often tends to be visually equivocal, presumably due to 
(i) a generally small size of the target and (ii) inherent technical diffi-
culties to visualize such a lesion on MRI [6], thereby leaving room for 
subjectivity. At the same time ‘quantification’ of features and semi-
quantitative metrics are not currently integrated in PI-RADS v2.1 in 
order to keep the reporting process as simple as possible. These factors 
lead to considerable variability in inter- and intrareader agreement 
[7–12]. 
Despite continuous improvement, an expert radiologist’s perfor-
mance using PI-RADS shows a mean sensitivity of 85 % for detection of 
significant PCa when following the interpretation suggestions of PI- 
RADS v.2.1 [13,14]. The performance tends to be inferior at low 
throughput centers [15]. 
In an attempt to simplify and speed up the reporting process of 
prostate MRI, we use a browser-based PI-RADS Score Calculator (PCalc) 
to facilitate navigation through the PI-RADS v2.1 decision tree and 
provide the radiologist with visual examples of the morphology of le-
sions for each PI-RADS score. We derived the hypothesis that for non- 
specialized radiologists reporting prostate MRI with the assistance of 
PCalc might reduce reading time and increase reproducibility without 
impairing the accuracy in detection of clinically significant prostate 
cancer (PCa). 
The purpose of this study was to compare the value of a browser- 
based PCalc to MRI reporting using the official PI-RADS v2.1 docu-
ment (PDoc) for non-specialized radiologists in terms of reporting effi-
ciency, interrater agreement and lesion-based diagnostic accuracy for 
clinically significant PCa. 
2. Material and methods 
The regional ethics committee approved this retrospective study and 
written general informed consent was available from all patients prior to 
the examination. The study was compliant with the Health Insurance 
Portability and Accountability Act (HIPAA). 
2.1. Study population 
Between September 2013 and April 2015, 105 consecutive treat-
ment-naïve men were included. Inclusion criterion were (i) a clinically 
indicated multiparametric MRI of the prostate at 3 T (Tesla) for either 
biopsy-proven PCa, elevated prostate specific antigen (PSA) and/or 
suspicious digital rectal examination, and (ii) who subsequently un-
derwent transperineal prostate mapping biopsy (TPMB) within <6 
months. Patients with an incomplete scan protocol (n = 3), patients who 
received TPMB more than once (n = 1) and patients with prior androgen 
deprivation therapy (n = 1) were excluded. The final study population 
comprised of 100 patients (median age, 64.8; range 47.5−78.2) with a 
mean PSA, 7.7 μg/L (range, 0.8−34.7). 
Patient demographics and a summary of histopathology data is 
shown in Table 1 . 
2.2. Technical background 
Images were acquired on 3 T MRI systems (MAGNETOM Skyra, 
SIEMENS Healthcare®, Erlangen, Germany) equipped with two inde-
pendent transmit channels (TimTX TrueShape, Siemens Healthcare, 
Erlangen, Germany). An 18-channel phased-array coil and a balloon- 
covered, expandable endorectal coil (ERC; Medrad, Warrendale, Pa) 
were used as receiver coils. 
T2-weighted turbo-spin echo images (T2w) were obtained in three 
orthogonal planes (transversal, sagittal and coronal), covering the whole 
prostate gland including the seminal vesicles. Diffusion-weighted im-
ages (DWI) were acquired in the transverse plane with identical orien-
tation as the T2w images. Apparent diffusion coefficient (ADC) 
parametric maps were calculated using a mono-exponential fit based on 
three obtained b-values (either 0-50-1000s/mm2 [n = 86] or 100, 600, 
1000s/mm2 [n = 14]). A high-b-value (1400s/mm2) was calculated 
based on a standard mono-exponential fit. Dynamic contrast enhanced 
images (DCE-MRI) were obtained in transverse sections using a 3D T1w 
spoiled gradient-echo pulse sequence with a temporal resolution of <8 s. 
The contrast agent Gadoterate meglumine (Dotarem; Guerbet, Darm-
stadt, Germany) was used with a dosage of 0.1 mmol/kg bodyweight. 
Contrast injection was performed with an automated MR injection sys-
tem (Spectris Solaris EP, MEDRAD MR Injector, Bayer HealthCare LCC, 
Whippany NJ) at a flow rate of 2 mL/sec. 
T1-weighted turbo-spin echo images (T1w) were additionally ob-
tained during the clinical routine but were not used in this study setup. 
Basic scan parameters of MRI sequences used for study purposes are 
shown in Table 2. 
2.3. PI-RADS score calculator (PCalc) 
The browser-based PCalc used in this study is freely accessible [16]. 
Table 1 
Patient demographics and histopathology data from transperineal prostate 
mapping biopsy (TPMB).  
Demographic Parameter Value 
Age (y)* 64.8 [47.5−78.2] 
PSA at time of MRI imaging (in μg/L)* 7.7 [0.8−34.7] 
Prostate volume at MRI (in ml)* 48.6 [14.9−135.5] 
PSA density at time of MRI imaging* 0.19 [0.02−0.37] 
Time interval between mpMRI and Histopathology (d)* 39.9 [1−161] 
Patients diagnosed with clinically significant cancer** 47/100 (47) 
Patients with additional TRUS biopsy <180d prior to MRI 11/100 (11)  
Prevalence of Index Gleason Scores on TPMB** 
3 + 4 19/47 (40.4) 
4 + 3 14/47 (29.8) 
4 + 4 5/47 (10.6) 
4 + 5 9/47 (19.1) 
Note: n = 100 patients are in the dataset. 
* Data are means; data in squared parentheses are ranges. 
** Data are absolute counts; data in parentheses are percentages. 
Table 2 
Basic scan parameters of MRI sequences used for study purposes.   
T2w T2w DWI DCE-MRI 
Number of 
averages 
3 1/2 2, 4, 8 – 
TR range (ms) 3260−5140 3130−4000 4900−5718 5.0−6.3 
TE range (ms) 93−97 97−102 69−96 1.8 
In-plane resolution 
(mm) 
0.27 × 0.27 2.5 × 2.4 0.7 × 0.7 1 × 0.6 
Slice thickness 
(mm) 
3 3 3 3 
Acquisition Plane Transverse Coronal/ 
Sagittal 
Transverse Transverse  
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It supports the user by providing step-by-step guidance throughout the 
assessment process, including visual examples of each PI-RADS lesion 
category in order to facilitate assigning a final PI-RADS score. 
Reporting pathway:  
1 First the user needs to address whether the lesion is located within 
the peripheral (PZ) or the transitional zone (TZ).  
2 For the PZ the user first has to select a DWI/ADC appearance of the 
lesion. Visual examples and the official PI-RADS v2.1 text de-
scriptions of a specific category are given. If the lesion appears to 
have a PI-RADS 3 DWI morphology, the user has to assess the DCE- 
MRI additionally in order to decide whether the lesion is ‘DCE pos-
itive’ or ‘DCE negative’ according to PI-RADS v2.1.  
3 For the TZ the user first has to select a T2w appearance. If the lesion 
appears to have a PI-RADS 2 or 3 T2w morphology, the user has to 
assess the DWI/ADC appearance of the lesion in order to get a final 
score. 
2.4. Reference standard 
All patients underwent transperineal prostate mapping biopsy 
(TPMB) performed within <6 months (mean [d], 39.9, range 1−161) 
after MRI. TPMB was performed under general anesthesia using a 5-mm 
brachytherapy transperineal template grid. Histopathology specimens 
were evaluated by dedicated genitourinary pathologists. The histopa-
thology results were documented (i) within an official, text-based 
document and (ii) on a TPMB report scheme, the latter allowing for 
visual correlation of the lesion in relation to the segmental anatomy of 
the gland. The report included the number, location and length of the 
lesions. Lesions with a Gleason score (GS) ≥3 + 4 were considered as 
clinically significant. If multiple lesions were present, the one with the 
highest GS was considered as index lesion. 
2.5. Readout 
Images were anonymized. One staff radiologist (initials blinded for 
review) with 6 years of experience in prostate MRI reporting identified 
the index lesion (if present) on the TPMB report schemes. After visual 
side-by-side matching of the pathology data with the MRI images, the 
radiologist marked the index lesion with an arrow (on either a T2w or 
DWI image, depending on where the lesion was depicted best) and 
stored the image as a screenshot in the corresponding patient’s anony-
mized image folder. In order to generate a pool of true negative lesions if 
pathology revealed no clinically significant tumor, the prostate of pa-
tients without PCa was divided into quadrants. For each patient (i) a 
quadrant (i. e. anterior left [1], posterior left [2], anterior right [3], 
posterior right [4]) was selected by using a randomizer tool which 
generated a random sequence of numbers from 1 to 4. Within each 
selected quadrant (ii) the radiologist (initials blinded for review) chose 
one lesion/morphologic finding and marked it with an arrow. 
Two radiology residents [R1] (initials blinded for review) with 4 
years of experience and [R2] (initials blinded for review) with 2 years of 
experience in reporting prostate MRIs under senior supervision) inde-
pendently performed the image readout in two separate sessions. Both 
readers had previously used the updated PI-RADS System within clinical 
routine (>50 prostate MRs) and thus were familiar with it. The readers 
were aware that patients received TPMB after MRI, but were blinded to 
the remaining clinical information. In both sessions the MRI scans were 
presented in random order. The first readout was performed without 
using the PCalc. Readers were instructed to use the official PI-RADS v2.1 
document [5] for assistance if they deemed it to be necessary. The sec-
ond readout of the same data set was performed after a time interval >6 
weeks and with new randomization codes in order to minimize recall 
bias. This time, the readers were instructed to use the PCalc for every 
lesion side-by-side on a separate monitor. The use of the PCalc was 
mandatory. The readers were instructed to assess the areas marked by an 
arrow on the corresponding screenshot according to the PI-RADS v2.1 
criteria [5]. Apart from the PI-RADS Score the readers had to measure 
the reading time starting with the actual reading process (i.e. when all 
necessary images were loaded and ready for interpretation) and ending 
with the final assessment of the lesion score. The readout was performed 
using an electronic reader form. 
2.6. Statistical analysis 
Demographic variables were summarized as means with ranges and 
absolute numbers with percentages. Categorical variables were sum-
marized as absolute figures. Kolmogorov-Smirnov test was used to assess 
the distribution of data. 
Wilcoxon signed rank test was used to evaluate the central tendency 
between PI-RADS Scores and reading time. 
Agreement for the attributed PI-RADS scores (inter- and intrareader) 
was assessed using intraclass-correlation coefficient (ICC, two-way 
random, single measures), including 95 % confidence intervals (CI). 
The ICC values were interpreted as follows: 0–0.40, poor agreement; 
0.41–0.58, fair agreement; 0.59–0.75, good agreement; 0.76–1.0, 
excellent agreement [17]. 
Based on binarized data for the presence of clinically significant PCa 
(PI-RADS scores 1–3 were deemed to be ‘negative’ and scores 4 and 5 
‘positive’), the area under the receiver-operating characteristics curve 
(AUC) was calculated for the according PI-RADS scores attained with 
PDoc and with PCalc. Measures of diagnostic performance - sensitivity, 
specificity, positive predictive value (PPV), negative predictive value 
(NPV) - were calculated. CIs for sensitivity, specificity and accuracy are 
presented as "exact" Clopper-Pearson confidence intervals. CIs for the 
positive and negative predictive values are the standard logit confidence 
intervals (CIs) [18]. Statistical significance was defined as 
non-overlapping 95 % CIs [20]. A p-value of <0.05 was considered 
statistically significant. 
Statistical analysis was performed with IBM SPSS statistical software 
(SPSS version 21; Chicago, Ill). 
3. Results 
3.1. Patient demographics and histopathology data 
Forty-seven of 100 patients (47 %) had clinically significant PCa on 
TPMB. The most prevalent Gleason score (GS) for an index lesions was 3 
+ 4, diagnosed in n = 19/47 (40.4 %) patients, followed by a GS of 4 + 3, 
diagnosed in n = 14/47 (29.8 %), a GS of 4 + 5, diagnosed in n = 9/47 
(19.1 %) and a GS of 4 + 4, diagnosed in n = 5/47 (10.6 %). Patient 
demographics and histopathology data from transperineal prostate 
mapping biopsy (TPMB) are shown in Table 1 . 
3.2. Reporting speed per lesion 
Average reading time was 35 s [range, 13–90] for R1 and 25 s [range, 
4–75] for R2, as compared to 21 s [range, 5–56] for R1 and 20 s [range, 
4–53] for R2 when reading with PDoc and PCalc, respectively. Cumu-
lative reading time was shorter when using PCalc for both readers (Time 
difference R1: -23:54 [mm:ss], and R2: -09:01 [mm:ss]). Difference in 
reading time was statistically significant for both readers (p < 0.05). 
Reading time per lesion is shown in Fig. 1, two lesion examples are 
shown in Fig. 3. 
R1 seemed to shorten reading time by using PCalc particularly when 
attributing PI-RADS 1, 2 and 3 scores to lesions (% range of mean time 
saved/lesion, 43.8–47.1 %), whereas R2 seemed to profit mainly for PI- 
RADS 1 lesions (% of mean time saved/lesion, 42.9 %) when using 
PCalc. Percentage (%) of mean time saved per PI-RADS score is shown in 
Table 3. 
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3.3. Agreement 
Interreader agreement between R1 and R2 regarding PI-RADS score 
was poor (ICC 0.56 [0.40, 0.68]) for the image set interpreted with PCalc 
and fair (ICC 0.69 [0.43, 0.82] for the image set with PDoc, respectively. 
Intrareader agreement regarding PI-RADS score was excellent for R1 
(ICC 0.85 [0.78, 0.90]) and R2 (ICC 0.81 [0.72, 0.87]). 
3.4. Lesion-based diagnostic accuracy 
Mean PI-RADS score for the analyzed data set was 2.7 and 3.2 (p <
0.001) for R1, and 3.2 and 3.3 (p = 0.45) for R2, for images read using 
PDoc and with PCalc. PI-RADS v2.1 scores attributed to the lesions for 
images using PDoc and PCalc are shown in Fig. 1. An example for the 
tendentially higher scoring using PCalc is shown in Fig. 4. 
AUCReader1 was 0.83 [95 %CI: 0.74, 0.92] using PDoc and 0.86 [95 % 
CI: 0.82, 0.95] using PCalc. AUCReader2 was 0.82 [95 %CI: 0.74, 0.91] 
using PDoc and 0.74 [95 %CI: 0.64, 0.83] using PCalc. ROC analysis 
revealed no statistically significant difference in diagnostic performance 
for both readers between images read using PDoc compared to PCalc 
with overlapping 95 %CIs. ROC curves for both readers with PDoc and 
PCalc are shown in Fig. 2. 
For R1, sensitivities were 64 % [95 %CI 49, 77] and 77 % [95 %CI 62, 
88] for PDoc and PCalc, respectively. For R2 the according sensitivities 
were 70 % [95 %CI 55, 83] and 64 % [95 %CI 49, 77]. Specificites were 
R1, 96 % [95 %CI 87, 100] and 87 % [95 %CI 75, 95] for PDoc and PCalc 
for R1 and 87 % [95 %CI 75, 95] and 77 % [95 %CI 64, 88] vor R2. 
Differences were not statistically significant with overlapping 95 %CIs. 
Index-lesion based diagnostic accuracy parameters of images read using 
Fig. 1. PI-RADS Scores and Reading Time. 
PI-RADS v2.1 scores attributed to the lesions for images acquired with PI-RADS Document and with PI-RADS Score Calculator (upper row) and reading time per 
lesion (lower row) are shown. 
Table 3 
Percentage (%) of mean time saved per PI-RADS Score using PI-RADS Score 
Calculator.  
PI-RADS 1 2 3 4 5 Mean 
Reader 1* 45.7 47.1 43.8 30.3 28.6 39.1 
Reader 2* 42.9 20.0 16.7 15.4 17.6 22.5 
Note: n = 100 patients are in the dataset. 
* Data are percentages. 
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PDoc and PCalc are shown in Table 4. 
4. Discussion 
Prostate Imaging and Reporting Data System (PI-RADS) is widely 
used for reporting prostate MRI. However, using PI-RADS based on the 
officially available document may be challenging and time-consuming, 
particularly for non-specialized radiologists. This may potentially 
impair the even wider application of this reporting algorithm in daily 
clinical routine. The results of this study suggest that the use of a simple, 
browser-based tool, which supports the radiologist to navigate along the 
diagnostic pathway to reach a final PI-RADS score, bears the potential to 
speed up reporting, without impairing interreader agreement or diag-
nostic accuracy. 
A software tool helping to find one’s way through a multi-branched 
decision tree in attaining a certain PI-RADS score may increase reading 
speed and reduce errors in misclassifying lesions due to eliminating 
wrong or irrelevant pathways. Using the PCalc both readers saved time 
by reporting approximately 30 % faster on average. The average per-
centage of time saved decreased with the severity of the score for both 
readers. Presenting only the necessary information at a given point 
within the decision process, as provided by PCalc, presumably acceler-
ates the decision process. Our results are in line with a study demon-
strating increased reporting efficiency in screening chest radiographs for 
Fig. 2. Diagnostic Accuracy. 
Receiver operating characteristic (ROC) curves for both readers with PI-RADS Document and with PI-RADS Score Calculator are shown. 
Fig. 3. Two Benign Lesions. 
Two examples of definitely benign lesions within the transitional zone (TZ) in men undergoing mpMRI of the prostate for elevated PSA. 
67-year-old man (A-D) demonstrating a completely encapsulated, T2w hyperintense lesion (A, T2w axial; B, DCE-MRI; C, DWI [b-1000 value]; D, ADC Map). The 
lesion was scored PI-RADS 1 by both readers, using PDoc and PCalc. R1 saved 5 s, R2 23 s when reading with PCalc. 
54-year-old man (E-H) demonstrating a partially obscured, T2w heterogeneous, centrally hypointense lesion, with an indistinct hypointense area on ADC (A, T2w 
axial; B, DCE-MRI; C, DWI [b-1000 value]; D, ADC Map). The lesion was scored PI-RADS 3 by both readers with PDoc and with PCalc. R1 saved 52 s, while R2 needed 
2 s longer when reading with PCalc. 
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tuberculosis using a custom software for computer-aided reporting [19]. 
As PI-RADS in its current version is still based on freely interpretable 
descriptions and does not include quantitative measures, there is 
inherent subjectivity in grading prostate lesions. The more experienced 
a radiologist becomes in judging lesions on MRI of the prostate, the more 
she or he may be bending the strict PI-RADS interpretation rules in order 
for a certain lesion to fall into a given category of likelihood for PCa. For 
example, even if a definite score is given according to strict application 
of the PI-RADS criteria, sometimes the lesion from a personal perspec-
tive of the radiologist seems to be more or less aggressive, particularly if 
the clinical or biochemical information provided by the referring 
clinician points into a certain direction. This in turn can tempt the 
radiologist to interpret lesion features in a way, which favor the initial 
‘intuition’. On one hand, including ‘intuition’ into interpretation of MRI 
may be beneficial as it allows for the radiologist’s experience to influ-
ence lesion categorization, on the other hand non-expert readers will 
most likely benefit from strict adherence to the PI-RADS algorithm. 
Especially for the latter group (for example resident doctors and radi-
ologists not working in high volume centers) a software-based tool for 
interpretation of prostate MR like PCalc may be helpful. We therefore 
expected the interreader agreement to improve by use of the PCalc 
which however was not the case. The difference in interreader agree-
ment did not significantly differ between the two imaging interpretation 
workflows and the degree of agreement achieved in this study is com-
parable with the results of other studies using PI-RADS reporting [7–12]. 
A lack of improvement in interreader agreement in our study suggests 
that the inherent subjectivity in rating prostatic lesions is not eliminated 
just by adhering to a tool such as the PCalc. The introduction of quan-
titative measures, such as ADC may increase interreader agreement. 
Several studies have shown the potential of this metric in assessing the 
aggressiveness in prostate tumors and discriminating clinically signifi-
cant from non-significant cancer [20,21]. Furthermore, ADC presents a 
reproducible metric even regarding MR system of different vendors 
[22]. However, an algorithm defined by a set of rules that is ideally 
supposed to be adopted by a wide range of radiologists must be simple 
and easily comprehensible. The evolution of the PI-RADS algorithms 
over time showed a trend away from quantification, as semiquantitative 
contrast kinetic parameters derived from DCE-MRI and spectroscopy 
have been removed in PI-RADS 2.0. This strategy introduces more 
reporting flexibility based on ‘intuition’, however at the cost of repro-
ducibility. To increase simplicity along with agreement will be one the 
major challenges in future PI-RADS versions. A software-based tool may 
be a step towards achieving those seemingly contradictory goals and 
could be included in a further version of the PI-RADS document. 
Diagnostic accuracy did not change significantly between the two 
interpretation workflows. Lesion-based sensitivity for detection of PCa 
Fig. 4. Two Tumorous Lesions. 
Two examples of tumorous lesions (both GS 3 + 4) within the peripheral zone (PZ) of men undergoing mpMRI of the prostate for elevated PSA. 
74-year-old man (A-D) demonstrating a focal, markedly hypointense lesion on ADC with hyperintense signal on the b-1000 image (A, T2w axial; B, DCE-MRI; C, DWI 
[b-1000 value]; D, ADC Map). The lesion was scored PI-RADS 5 by both readers using PDoc and PI-RADS 4 by R1 and PI-RADS 5 by R2 using PCalc. 
58-year-old man (E-H) demonstrating a hypointense lesion on ADC, with irregular margins (non-focal), abutting the prostate capsule (A, T2w axial; B, DCE-MRI; C, 
DWI [b-1000 value]; D, ADC Map). The lesion was scored PI-RADS 2 by both readers with PDoc and PI-RADS 3 with PCalc. Although scoring falsely negative, the case 
demonstrates the tendentially more offensive scoring using PCalc. 
Table 4 
Index-lesion based diagnostic accuracy of images read without and with PI- 
RADS Score Calculator.  
Dg Acc Parameter 
Reader 1 Reader 2 
PDoc† PCalc PDoc† PCalc 
True Positives 30 36 33 30 
True Negatives 51 46 46 41 
False Positives 2 7 7 12 
False Negatives 17 11 14 17 














Positive Predictive Value 
* 




















Note: Values are expressed as probabilities (%). 
* Data in brackets are 95% Confidence Intervals (CI). Estimates dependent on 
disease prevalence. Prevalence of clinically significant cancer within the dataset: 
47 %. 
† Conventional PI-RADS v2.1 Document. 
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ranged between 64–77 %, which is below an average of 85 %- a value 
derived form a representative meta-analysis [13] assessing diagnostic 
accuracy using PI-RADS v2. Probably the lack of reporting experience of 
the two readers who were resident radiologists explains this difference 
in sensitivity as compared to the expert reader’s performance in the 
above-mentioned meta-analysis. 
Our study had limitations, first, we chose two non-expert readers for 
this study setup, as we assumed that particularly those radiologists 
would profit from this tool. Therefore, the results may not be applicable 
to experts or more experienced senior radiologists. However, the pri-
mary aim of this study was to investigate the difference in reporting time 
as a measure of efficacy when using the PI-RADS algorithm and inter-
reader agreement, an issue which is especially pronounced in younger 
inexperienced radiologists and which is relevant in teaching hospitals 
with resident or fellowship programs. Second, the methodology for in-
clusion of ‘truly negative’ lesions is subject to a selection bias. However, 
along with the topographic restriction for lesion selection, the image set 
was identical for both readouts, without and with PCalc, hence (if pre-
sent) the bias was affecting both in the same way. Moreover, diagnostic 
accuracy was assessed on a lesion basis, hence the results must be 
interpreted with caution when being compared with cancer detection 
data on a patient level. 
In conclusion, the present study demonstrates that reporting speed in 
prostate MRI may be increased by using a browser-based PI-RADS Score 
Calculator as compared to reporting using the official PI-RADS v2.1 
document without impairing interreader agreement or diagnostic ac-
curacy for detection of clinically significant PCa. Providing such a 
software tool in a revised version of the PI-RADS document may further 
increase the wide distribution of this reporting algorithm and may 
simplify its application. 
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